Arterial spin labeled MRI in prodromal Alzheimer's disease: A multi-site study

Ze Wang1, Sandhitsu R Das, Sharon X Xie

  • 1Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA ; Center for Functional Neuroimaging, University of Pennsylvania, Philadelphia, PA, USA ; Penn Memory Center, University of Pennsylvania, Philadelphia, PA, USA.

Neuroimage. Clinical
|November 2, 2013
PubMed

Insights

Arterial Spin Labeled perfusion MRI (ASL MRI) shows reduced cerebral blood flow (CBF) in mild Alzheimer's Disease (AD) and mild cognitive impairment. Combining ASL MRI with hippocampal volume aids in early AD diagnosis and tracking disease severity.

Area of Science:

  • Neuroimaging
  • Neurology
  • Medical Imaging

Background:

  • Alzheimer's Disease (AD) diagnosis relies on clinical assessment and biomarkers.
  • Cerebral blood flow (CBF) changes are implicated in AD progression.
  • Arterial Spin Labeled (ASL) MRI offers a non-invasive method to measure CBF.

Purpose of the Study:

  • To evaluate ASL MRI for measuring CBF differences across the Alzheimer's Disease continuum.
  • To assess the association of CBF and hippocampal volume with disease severity.
  • To determine the utility of combined functional and structural MRI for AD diagnosis.

Main Methods:

  • ASL MRI was used to measure CBF in cognitively normal (CN), early/late mild cognitive impairment (EMCI/LMCI), and AD participants from the ADNI cohort.
  • Hippocampal volumes were compared across groups.
  • Associations between CBF, hippocampal volume, and Clinical Dementia Rating scale sum of boxes (CDR SB) were analyzed.

Main Results:

  • Significant hypoperfusion (reduced CBF) was observed in LMCI and AD groups compared to CN.
  • Only AD patients showed significantly reduced hippocampal volumes compared to CN.
  • Both CBF and hippocampal volume were significantly associated with CDR SB, providing independent predictive value.

Conclusions:

  • ASL MRI is a feasible multi-site biomarker for detecting hypoperfusion in AD.
  • Combining ASL MRI with hippocampal volume measurement enhances the prediction of AD status and severity.
  • These multimodal MRI approaches show promise for early AD diagnosis and monitoring.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K